Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT05644743

Clinical Transformation of Organoid Model to Predict the Efficacy of GC in the Treatment of Intrahepatic Cholangiocarcinoma

Status
Not Yet Recruiting
Phase
Study type
Observational
Enrollment
40 (estimated)
Sponsor
Chengjun Sui,MD · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

The clinical incidence of intrahepatic cholangiocarcinoma (ICC) is high and insidious, and the prognosis of advanced patients is poor. The clinical manifestations of traditional chemotherapy GC and emerging targeted therapy are different in most patients, and there is still no effective scheme to evaluate the differences in individual patient reactivity. Patient-derived tumor organoids (PDO) are 3D-cultured tissues based on tumor cell dryness that reproduce a variety of biological characteristics of parental tumors in vitro and have similar drug responsiveness to tumors in vivo. This project plans to use clinical cases and optimized organoid culture system to first construct relevant organoids from unresectable ICC patient puncture samples. Secondly, based on the organoid model of intrahepatic cholangiocarcinoma, the clinical efficacy of GC regimen was predicted, and in vitro and in vivo drug screening was conducted to explore the guidance of patient-derived tumor organoids for clinical treatment. Then, multi-omics data of organoids and in vitro and in vivo drug efficacy evaluation model were used to explore the drug resistance genes of intrahepatic cholangiocarcinoma, providing the basis for personalized drug screening and efficacy evaluation of intrahepatic cholangiocarcinoma.

Conditions

Interventions

TypeNameDescription
DEVICEgemcitabine + cisplatinGemcitabine intravenous drip, day 1, 8; Cisplatin intravenous drip, day 1; 3 weeks is a cycle, and 6 cycles are used continuously.

Timeline

Start date
2023-01-01
Primary completion
2025-12-01
Completion
2026-12-01
First posted
2022-12-09
Last updated
2022-12-09

Source: ClinicalTrials.gov record NCT05644743. Inclusion in this directory is not an endorsement.